DISEÑO DE UN OBJETO VIRTUAL DE APRENDIZAJE SOPORTANDO EN ENFOQUE SERIOUS GAME PARA EL RETORNO EFICIENTE DE NEUMÁTICOS FUERA DE USO PARA EMPRESA DE TRANSPORTE DE CARGA TERRESTRE EN LA CIUDAD DE BOGOTÁ

El presente artículo muestra el avance del proyecto que busca desarrollar un objeto virtual de aprendizaje basado en el enfoque de serious game paraun modelo de gestión de logística inversa de llantas usadas en la ciudad de Bogotá. A través del desarrollo de las fases de: planeación, producción, implementación y prueba, se logró transformar la información del estudio base (técnico - logístico), en un prototipo funcional de videojuego que facilitarael aprendizaje del modelo técnico entre los actores involucrados. El producto fue sometido a una evaluación previa con una muestra de 10 personasque interactuaron con la herramienta y registraron su experiencia de usuario a través de una encuesta. Los resultados se analizan descriptivamente enel presente artículo, resaltando una gran aceptación del entorno gráico y las animaciones. Sin embargo, deben realizarse ajustes signiicativos en lamecánica del juego para impactar en el aprendizaje del modelo propuest

Kursito "Desarrollo e implementación de un emprendimiento basado en la creación de una plataforma web de aprendizaje a distancia especializado en e-commerce y marketing digital en Lima Metropolitana 2022"

Actualmente, el número de conocimientos requeridos por distintas organizaciones en sus respectivos anuncios de ofertas laborales es bastante elevado, motivo por el cual los aplicantes se encuentran en la necesidad de capacitarse y/o especializarse de forma constante. De acuerdo con ello, dos de los cursos más demandados por los jóvenes y adultos jóvenes del país resultan ser E-Commerce y Marketing Digital. Por otro lado, la pandemia de COVID-19 ha significado un cambio revolucionario para todas las industrias, viéndose el cambio más radical e importante en la industria de la educación. En ese sentido, el aprendizaje se ha visto nutrido por los diferentes avances en materia tecnológica, siendo las plataformas de aprendizaje digital aquellas herramientas que registraron crecimientos de casi 400%. El presente trabajo de investigación abarca la creación de Kursito, la plataforma web de aprendizaje digital especializado E-Commerce y Marketing Digital que busca revolucionar el mercado de la educación a distancia a partir de la oferta de un servicio completamente flexible y adaptable a las necesidades específicas de cada usuario.Currently, the number of skills required by different organizations in their respective job advertisements is quite high, which is why applicants find themselves in need of constant training and/or specialization. Accordingly, two of the most demanded courses by the country's youth and young adults happen to be E-Commerce and Digital Marketing. On the other hand, the COVID-19 pandemic has meant a revolutionary change for all industries, with the most radical and important change being seen in the education industry. In that sense, learning has been nurtured by the different advances in technology, being the digital learning platforms, those tools that registered growths of almost 400%. This research work covers the creation of Kursito, the digital learning web platform specialized in E-Commerce and Digital Marketing that seeks to revolutionize the distance learning market by offering a completely flexible service that can be adapted to the specific needs of each user.Trabajo de investigació

The burden of non-SARS-CoV2 viral lower respiratory tract infections in hospitalized children in Barcelona (Spain): A long-term, clinical, epidemiologic and economic study

Cost of illness; Hospitalization; VirusesCost de la malaltia; Hospitalització; VirusCoste de la enfermedad; Hospitalización; VirusBackground Viral lower respiratory tract infections (LRTI) are the leading cause of hospitalization in children. In Catalonia (Spain), information is scarce about the burden of viral LRTIs in paediatric hospitalizations. The aim of this study is to describe epidemiological, clinical, virological and economic features of paediatric hospitalizations due to viral LRTI. Methods From October 2012 to December 2020, children aged <16 years admitted to a tertiary paediatric hospital in Catalonia (Spain) with confirmed viral LRTI were included in the study. Virus seasonality, prevalence, age and sex distribution, clinical characteristics, hospital costs and bed occupancy rates were determined. Results A total of 3,325 children were included (57.17% male, 9.44% with comorbidities) accounting for 4056 hospitalizations (32.47% ≤ 12 months): 53.87% with wheezing/asthma, 37.85% with bronchiolitis and 8.28% with pneumonia. The most common virus was respiratory syncytial virus (RSV) (52.59%). Influenza A was associated with pneumonia (odds ratio [OR] 7.75) and caused longer hospitalizations (7 ± 31.58 days), while RSV was associated with bronchiolitis (OR 6.62) and was the most frequent reason for admission to the paediatric intensive care unit (PICU) (11.23%) and for respiratory support (78.76%). Male sex, age ≤12 months, chronic conditions and bronchiolitis significantly increased the odds of PICU admission. From October to May, viral LRTIs accounted for 12.36% of overall hospital bed days. The total hospitalization cost during the study period was €16,603,415. Conclusions Viral LRTIs are an important cause of morbidity, hospitalization and PICU admission in children. The clinical burden is associated with significant bed occupancy and health-care costs, especially during seasonal periods.This work was partially supported by the Spanish National R + D + I Plan 2008–2011 and by the Carlos III Health Institute, the Subdirectorate-General of Networks and Cooperative Research Centers, the Spanish Ministry of Economy and Competitiveness, the Spanish Network for Research in Infectious Diseases (REIPI RD16/0016/0003), and by the Health Research Fund, the Spanish Ministry of Economy and Competitiveness (grants FIS PI14/01838 and FIS PI18/00685), and the European Regional Development Fund (ERDF). Editorial assistance for revision of the English language and edition of the manuscript was provided by Vanessa Marfil, medical writer from MSC (Spain) and funded by Sanofi

Canagliflozin and renal outcomes in type 2 diabetes and nephropathy

BACKGROUND Type 2 diabetes mellitus is the leading cause of kidney failure worldwide, but few effective long-term treatments are available. In cardiovascular trials of inhibitors of sodium–glucose cotransporter 2 (SGLT2), exploratory results have suggested that such drugs may improve renal outcomes in patients with type 2 diabetes. METHODS In this double-blind, randomized trial, we assigned patients with type 2 diabetes and albuminuric chronic kidney disease to receive canagliflozin, an oral SGLT2 inhibitor, at a dose of 100 mg daily or placebo. All the patients had an estimated glomerular filtration rate (GFR) of 30 to &lt;90 ml per minute per 1.73 m2 of body-surface area and albuminuria (ratio of albumin [mg] to creatinine [g], &gt;300 to 5000) and were treated with renin–angiotensin system blockade. The primary outcome was a composite of end-stage kidney disease (dialysis, transplantation, or a sustained estimated GFR of &lt;15 ml per minute per 1.73 m2), a doubling of the serum creatinine level, or death from renal or cardiovascular causes. Prespecified secondary outcomes were tested hierarchically. RESULTS The trial was stopped early after a planned interim analysis on the recommendation of the data and safety monitoring committee. At that time, 4401 patients had undergone randomization, with a median follow-up of 2.62 years. The relative risk of the primary outcome was 30% lower in the canagliflozin group than in the placebo group, with event rates of 43.2 and 61.2 per 1000 patient-years, respectively (hazard ratio, 0.70; 95% confidence interval [CI], 0.59 to 0.82; P=0.00001). The relative risk of the renal-specific composite of end-stage kidney disease, a doubling of the creatinine level, or death from renal causes was lower by 34% (hazard ratio, 0.66; 95% CI, 0.53 to 0.81; P&lt;0.001), and the relative risk of end-stage kidney disease was lower by 32% (hazard ratio, 0.68; 95% CI, 0.54 to 0.86; P=0.002). The canagliflozin group also had a lower risk of cardiovascular death, myocardial infarction, or stroke (hazard ratio, 0.80; 95% CI, 0.67 to 0.95; P=0.01) and hospitalization for heart failure (hazard ratio, 0.61; 95% CI, 0.47 to 0.80; P&lt;0.001). There were no significant differences in rates of amputation or fracture. CONCLUSIONS In patients with type 2 diabetes and kidney disease, the risk of kidney failure and cardiovascular events was lower in the canagliflozin group than in the placebo group at a median follow-up of 2.62 years

Risk profiles and one-year outcomes of patients with newly diagnosed atrial fibrillation in India: Insights from the GARFIELD-AF Registry.

BACKGROUND: The Global Anticoagulant Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF) is an ongoing prospective noninterventional registry, which is providing important information on the baseline characteristics, treatment patterns, and 1-year outcomes in patients with newly diagnosed non-valvular atrial fibrillation (NVAF). This report describes data from Indian patients recruited in this registry. METHODS AND RESULTS: A total of 52,014 patients with newly diagnosed AF were enrolled globally; of these, 1388 patients were recruited from 26 sites within India (2012-2016). In India, the mean age was 65.8 years at diagnosis of NVAF. Hypertension was the most prevalent risk factor for AF, present in 68.5% of patients from India and in 76.3% of patients globally (P < 0.001). Diabetes and coronary artery disease (CAD) were prevalent in 36.2% and 28.1% of patients as compared with global prevalence of 22.2% and 21.6%, respectively (P < 0.001 for both). Antiplatelet therapy was the most common antithrombotic treatment in India. With increasing stroke risk, however, patients were more likely to receive oral anticoagulant therapy [mainly vitamin K antagonist (VKA)], but average international normalized ratio (INR) was lower among Indian patients [median INR value 1.6 (interquartile range {IQR}: 1.3-2.3) versus 2.3 (IQR 1.8-2.8) (P < 0.001)]. Compared with other countries, patients from India had markedly higher rates of all-cause mortality [7.68 per 100 person-years (95% confidence interval 6.32-9.35) vs 4.34 (4.16-4.53), P < 0.0001], while rates of stroke/systemic embolism and major bleeding were lower after 1 year of follow-up. CONCLUSION: Compared to previously published registries from India, the GARFIELD-AF registry describes clinical profiles and outcomes in Indian patients with AF of a different etiology. The registry data show that compared to the rest of the world, Indian AF patients are younger in age and have more diabetes and CAD. Patients with a higher stroke risk are more likely to receive anticoagulation therapy with VKA but are underdosed compared with the global average in the GARFIELD-AF. CLINICAL TRIAL REGISTRATION-URL: http://www.clinicaltrials.gov. Unique identifier: NCT01090362

Newer generations of multi-target CAR and STAb-T immunotherapeutics: NEXT CART Consortium as a cooperative effort to overcome current limitations

Adoptive T cellular immunotherapies have emerged as relevant approaches for treating cancer patients who have relapsed or become refractory (R/R) to traditional cancer treatments. Chimeric antigen receptor (CAR) T-cell therapy has improved survival in various hematological malignancies. However, significant limitations still impede the widespread adoption of these therapies in most cancers. To advance in this field, six research groups have created the “NEXT Generation CART MAD Consortium” (NEXT CART) in Madrid’s Community, which aims to develop novel cell-based immunotherapies for R/R and poor prognosis cancers. At NEXT CART, various basic and translational research groups and hospitals in Madrid concur to share and synergize their basic expertise in immunotherapy, gene therapy, and immunological synapse, and clinical expertise in pediatric and adult oncology. NEXT CART goal is to develop new cell engineering approaches and treatments for R/R adult and pediatric neoplasms to evaluate in multicenter clinical trials. Here, we discuss the current limitations of T cell-based therapies and introduce our perspective on future developments. Advancement opportunities include developing allogeneic products, optimizing CAR signaling domains, combining cellular immunotherapies, multi-targeting strategies, and improving tumor-infiltrating lymphocytes (TILs)/T cell receptor (TCR) therapy. Furthermore, basic studies aim to identify novel tumor targets, tumor molecules in the tumor microenvironment that impact CAR efficacy, and strategies to enhance the efficiency of the immunological synapse between immune and tumor cells. Our perspective of current cellular immunotherapy underscores the potential of these treatments while acknowledging the existing hurdles that demand innovative solutions to develop their potential for cancer treatment fully

Dementia in Latin America : paving the way towards a regional action plan

Regional challenges faced by Latin American and Caribbean countries (LACs) to fight dementia, such as heterogeneity, diversity, political instabilities, and socioeconomic disparities, can be addressed more effectively grounded in a collaborative setting based on the open exchange of knowledge. In this work, the Latin American and Caribbean Consortium on Dementia (LAC-CD) proposes an agenda for integration to deliver a Knowledge to Action Framework (KtAF). First, we summarize evidence-based strategies (epidemiology, genetics, biomarkers, clinical trials, nonpharmacological interventions, networking and translational research) and align them to current global strategies to translate regional knowledge into actions with transformative power. Then, by characterizing genetic isolates, admixture in populations, environmental factors, and barriers to effective interventions and mapping these to the above challenges, we provide the basic mosaics of knowledge that will pave the way towards a KtAF. We describe strategies supporting the knowledge creation stage that underpins the translational impact of KtAF

Transverse polarization measurement of Λ hyperons in pNe collisions at √sNN = 68.4 GeV with the LHCb detector

A measurement of the transverse polarization of the Λ andΛ hyperons in pNe fixed-target collisions at √ sNN = 68.4 GeV is presented using data collected by the LHCb detector. The polarization is studied using the decay Λ → pπ− together with its charge conjugated process, the integrated values measured are PΛ = 0.029 ± 0.019 (stat) ± 0.012 (syst), PΛ = 0.003 ± 0.023 (stat) ± 0.014 (syst). Furthermore, the results are shown as a function of the Feynman x variable, transverse momentum, pseudorapidity and rapidity of the hyperons, and are compared with previous measurements

Search for the lepton-flavor violating decay Bs0 → ϕμ±τ∓

A search for the lepton-flavor violating decays B0 s → ϕμ±τ∓ is presented, using a sample of proton-proton collisions at center-of-mass energies of 7, 8, and 13 TeV, collected with the LHCb detector and corresponding to a total integrated luminosity of 9 fb−1. The τ leptons are selected using decays with three charged pions. No significant excess is observed, and an upper limit on the branching fraction is determined to be B(B0 s → ϕμ±τ∓) &lt; 1.0 × 10−5 at 90% confidence level